A new protein variant underlies the ability of gastric cancers to resist an otherwise effective family of chemotherapy drugs.
The study by a multidisciplinary team at Weill Cornell Medicine combined clinical insight, laboratory experiments and sophisticated computational analysis to determine how some tumor cells resist a family of chemotherapy drugs called taxanes. The results suggest a treatment strategy that could improve the prognoses of many patients with cancer.
“We identified a novel variant that is clinically prevalent and is expressed in more than 60 percent of patients with gastric cancer and operates with a mechanism that’s different from previously discovered ones,” said co-senior author Dr. Paraskevi Giannakakou.
Dr. Manish Shah noticed that most patients with gastric cancer live less than a year. He also said: “If we could figure out a way to make the taxanes more effective, we could have a bigger impact on patients”.
Please follow the link for more info.
BIOMEDICA CRO is ready to collect high-quality human biospecimens to provide with all needed samples and associated data for their preclinical studies. Please email us to start our collaboration: office@biomedica-cro.com or visit our page with relevant biospecimens options.
